Chengdu Kanghong Pharmaceutical Group's subsidiary, KHN921 injection, has received approval from the US FDA to conduct clinical trials.

Chengdu Kanghong Pharmaceutical Group (002773.SZ) announced that its subsidiary, Chengdu Hongji Biotechnology Co., Ltd. (referred to as "Hongji Biotech"), has received an email from the Food and Drug Administration (FDA) of the United States permitting the clinical trial of KHN921 injection in the U.S. KHN921 injection is an AAV gene therapy product developed independently by Hongji Biotech for the treatment of MYBPC3 gene mutation-related hypertrophic cardiomyopathy (HCM). The product uses a novel adenovirus delivery vector based on the company's proprietary intellectual property and designed for cell-specific receptors, employing an innovative method of administration to efficiently target myocardial tissue. By delivering the functional target gene to the patient's myocardial cells through the AAV vector, the product corrects the functional defects caused by pathogenic gene mutations at the genetic level, improving myocardial structure and function, delaying or reversing disease progression, and reducing the risk of severe cardiovascular events.